Annual CFF
$40.03 M
+$30.03 M+300.33%
31 December 2023
Summary:
Galectin Therapeutics annual cash flow from financing activities is currently $40.03 million, with the most recent change of +$30.03 million (+300.33%) on 31 December 2023. During the last 3 years, it has risen by +$39.77 million (+15121.67%). GALT annual CFF is now -20.05% below its all-time high of $50.08 million, reached on 31 December 2019.GALT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$10.00 M
-$376.00 K-3.62%
30 September 2024
Summary:
Galectin Therapeutics quarterly cash flow from financing activities is currently $10.00 million, with the most recent change of -$376.00 thousand (-3.62%) on 30 September 2024. Over the past year, it has dropped by -$33.00 thousand (-0.33%). GALT quarterly CFF is now -78.90% below its all-time high of $47.40 million, reached on 30 June 2019.GALT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$40.38 M
-$33.00 K-0.08%
30 September 2024
Summary:
Galectin Therapeutics TTM cash flow from financing activities is currently $40.38 million, with the most recent change of -$33.00 thousand (-0.08%) on 30 September 2024. Over the past year, it has increased by +$343.00 thousand (+0.86%). GALT TTM CFF is now -20.43% below its all-time high of $50.74 million, reached on 30 June 2019.GALT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +300.3% | -0.3% | +0.9% |
| 3 y3 years | +10000.0% | 0.0% | +50.6% |
| 5 y5 years | +160.3% | +4429.0% | -18.1% |
GALT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | >+9999.0% | -3.6% | -0.1% | +303.8% | |
| 5 y | 5 years | -20.1% | >+9999.0% | -40.5% | +4429.0% | -19.4% | >+9999.0% |
| alltime | all time | -20.1% | -78.9% | +1100.0% | -20.4% | +3126.7% |
Galectin Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.00 M(-3.6%) | $40.38 M(-0.1%) |
| June 2024 | - | $10.38 M(+3.8%) | $40.41 M(+0.9%) |
| Mar 2024 | - | $10.00 M(0.0%) | $40.03 M(0.0%) |
| Dec 2023 | $40.03 M(+300.3%) | $10.00 M(-0.3%) | $40.03 M(0.0%) |
| Sept 2023 | - | $10.03 M(+0.3%) | $40.03 M(+33.4%) |
| June 2023 | - | $10.00 M(0.0%) | $30.00 M(+50.0%) |
| Mar 2023 | - | $10.00 M(0.0%) | $20.00 M(+100.0%) |
| Dec 2022 | $10.00 M(-72.8%) | $10.00 M(>+9900.0%) | $10.00 M(+0.0%) |
| Sept 2022 | - | $0.00(0.0%) | $10.00 M(-50.0%) |
| June 2022 | - | $0.00(0.0%) | $20.00 M(-45.7%) |
| Mar 2022 | - | $0.00(-100.0%) | $36.81 M(0.0%) |
| Dec 2021 | $36.81 M(>+9900.0%) | $10.00 M(-0.0%) | $36.81 M(+37.3%) |
| Sept 2021 | - | $10.00 M(-40.5%) | $26.82 M(+59.5%) |
| June 2021 | - | $16.82 M(>+9900.0%) | $16.82 M(>+9900.0%) |
| Mar 2021 | - | $0.00(0.0%) | $44.00 K(-83.3%) |
| Dec 2020 | $263.00 K(-99.5%) | $0.00(0.0%) | $263.00 K(-77.4%) |
| Sept 2020 | - | $0.00(-100.0%) | $1.17 M(+24.7%) |
| June 2020 | - | $44.00 K(-79.9%) | $934.00 K(-98.1%) |
| Mar 2020 | - | $219.00 K(-75.7%) | $48.29 M(-3.6%) |
| Dec 2019 | $50.08 M(+225.6%) | $902.00 K(-490.5%) | $50.08 M(+1.6%) |
| Sept 2019 | - | -$231.00 K(-100.5%) | $49.30 M(-2.9%) |
| June 2019 | - | $47.40 M(+2266.5%) | $50.74 M(+292.4%) |
| Mar 2019 | - | $2.00 M(+1515.3%) | $12.93 M(-15.9%) |
| Dec 2018 | $15.38 M(+329.2%) | $124.00 K(-89.8%) | $15.38 M(+0.8%) |
| Sept 2018 | - | $1.22 M(-87.3%) | $15.25 M(+1.7%) |
| June 2018 | - | $9.59 M(+115.4%) | $14.99 M(+154.6%) |
| Mar 2018 | - | $4.45 M(<-9900.0%) | $5.89 M(+64.4%) |
| Dec 2017 | $3.58 M(-39.5%) | -$1000.00(-100.1%) | $3.58 M(-53.8%) |
| Sept 2017 | - | $954.00 K(+96.7%) | $7.75 M(-6.6%) |
| June 2017 | - | $485.00 K(-77.4%) | $8.30 M(+2.8%) |
| Mar 2017 | - | $2.15 M(-48.5%) | $8.07 M(+36.2%) |
| Dec 2016 | $5.92 M(-56.8%) | $4.17 M(+177.9%) | $5.92 M(-45.6%) |
| Sept 2016 | - | $1.50 M(+483.7%) | $10.88 M(+15.5%) |
| June 2016 | - | $257.00 K(>+9900.0%) | $9.43 M(+2.8%) |
| Mar 2016 | - | $0.00(-100.0%) | $9.17 M(-33.1%) |
| Dec 2015 | $13.70 M(-56.5%) | $9.13 M(>+9900.0%) | $13.70 M(+144.1%) |
| Sept 2015 | - | $41.00 K(>+9900.0%) | $5.61 M(-0.3%) |
| June 2015 | - | $0.00(-100.0%) | $5.63 M(-4.1%) |
| Mar 2015 | - | $4.53 M(+335.8%) | $5.87 M(-81.3%) |
| Dec 2014 | $31.46 M(+265.5%) | $1.04 M(+1633.3%) | $31.46 M(-4.2%) |
| Sept 2014 | - | $60.00 K(-75.1%) | $32.84 M(-15.5%) |
| June 2014 | - | $241.00 K(-99.2%) | $38.88 M(+0.6%) |
| Mar 2014 | - | $30.12 M(+1144.8%) | $38.66 M(+349.0%) |
| Dec 2013 | $8.61 M | $2.42 M(-60.3%) | $8.61 M(+39.1%) |
| Sept 2013 | - | $6.10 M(>+9900.0%) | $6.19 M(+6776.7%) |
| June 2013 | - | $13.00 K(-83.1%) | $90.00 K(+16.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | $77.00 K(>+9900.0%) | $77.00 K(-99.3%) |
| Dec 2012 | $10.40 M(+67.9%) | $0.00(0.0%) | $10.40 M(0.0%) |
| Sept 2012 | - | $0.00(0.0%) | $10.40 M(-10.5%) |
| June 2012 | - | $0.00(-100.0%) | $11.62 M(-18.0%) |
| Mar 2012 | - | $10.40 M(>+9900.0%) | $14.18 M(+128.8%) |
| Dec 2011 | $6.20 M(-29.1%) | $0.00(-100.0%) | $6.20 M(-37.1%) |
| Sept 2011 | - | $1.22 M(-52.4%) | $9.86 M(+4.7%) |
| June 2011 | - | $2.56 M(+5.5%) | $9.42 M(-10.6%) |
| Mar 2011 | - | $2.42 M(-33.8%) | $10.54 M(+20.5%) |
| Dec 2010 | $8.74 M(+128.8%) | $3.66 M(+370.4%) | $8.74 M(+53.7%) |
| Sept 2010 | - | $778.00 K(-78.8%) | $5.69 M(+3.4%) |
| June 2010 | - | $3.67 M(+483.2%) | $5.50 M(+77.4%) |
| Mar 2010 | - | $630.00 K(+4.1%) | $3.10 M(-18.8%) |
| Dec 2009 | $3.82 M(+4.5%) | $605.00 K(+2.0%) | $3.82 M(+18.8%) |
| Sept 2009 | - | $593.00 K(-53.5%) | $3.22 M(+13.9%) |
| June 2009 | - | $1.27 M(-5.5%) | $2.82 M(+79.9%) |
| Mar 2009 | - | $1.35 M(>+9900.0%) | $1.57 M(-57.1%) |
| Dec 2008 | $3.65 M(+237.8%) | $1000.00(-99.5%) | $3.65 M(-27.9%) |
| Sept 2008 | - | $200.00 K(+900.0%) | $5.07 M(+7.8%) |
| June 2008 | - | $20.00 K(-99.4%) | $4.70 M(+4.1%) |
| Mar 2008 | - | $3.43 M(+142.5%) | $4.52 M(+317.4%) |
| Dec 2007 | $1.08 M(-87.0%) | $1.42 M(-947.9%) | $1.08 M(-181.1%) |
| Sept 2007 | - | -$167.00 K(0.0%) | -$1.33 M(+14.3%) |
| June 2007 | - | -$167.00 K(<-9900.0%) | -$1.17 M(+16.7%) |
| Mar 2007 | - | $0.00(-100.0%) | -$1.00 M(-112.0%) |
| Dec 2006 | $8.30 M(>+9900.0%) | -$1.00 M(<-9900.0%) | $8.30 M(-10.8%) |
| Sept 2006 | - | $0.00(0.0%) | $9.30 M(0.0%) |
| June 2006 | - | $0.00(-100.0%) | $9.30 M(0.0%) |
| Mar 2006 | - | $9.30 M(>+9900.0%) | $9.30 M(>+9900.0%) |
| Dec 2005 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2005 | - | $0.00(0.0%) | $2000.00(-100.0%) |
| June 2005 | - | $0.00(0.0%) | $5.51 M(-41.9%) |
| Mar 2005 | - | $0.00(-100.0%) | $9.50 M(0.0%) |
| Dec 2004 | $9.50 M(-4.5%) | $2000.00(-100.0%) | $9.50 M(-29.9%) |
| Sept 2004 | - | $5.51 M(+38.4%) | $13.55 M(+11.0%) |
| June 2004 | - | $3.98 M(>+9900.0%) | $12.20 M(+40.1%) |
| Mar 2004 | - | $0.00(-100.0%) | $8.71 M(-12.4%) |
| Dec 2003 | $9.94 M(+180.0%) | $4.06 M(-2.6%) | $9.94 M(+32.7%) |
| Sept 2003 | - | $4.16 M(+748.1%) | $7.49 M(+62.1%) |
| June 2003 | - | $491.00 K(-60.2%) | $4.62 M(-0.1%) |
| Mar 2003 | - | $1.23 M(-23.2%) | $4.63 M(+30.3%) |
| Dec 2002 | $3.55 M(+9.0%) | $1.61 M(+24.1%) | $3.55 M(+82.5%) |
| Sept 2002 | - | $1.29 M(+161.5%) | $1.95 M(+198.8%) |
| June 2002 | - | $495.00 K(+217.3%) | $651.00 K(+317.3%) |
| Mar 2002 | - | $156.00 K | $156.00 K |
| Dec 2001 | $3.26 M | - | - |
FAQ
- What is Galectin Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Galectin Therapeutics?
- What is Galectin Therapeutics annual CFF year-on-year change?
- What is Galectin Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly CFF year-on-year change?
- What is Galectin Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Galectin Therapeutics?
- What is Galectin Therapeutics TTM CFF year-on-year change?
What is Galectin Therapeutics annual cash flow from financing activities?
The current annual CFF of GALT is $40.03 M
What is the all time high annual CFF for Galectin Therapeutics?
Galectin Therapeutics all-time high annual cash flow from financing activities is $50.08 M
What is Galectin Therapeutics annual CFF year-on-year change?
Over the past year, GALT annual cash flow from financing activities has changed by +$30.03 M (+300.33%)
What is Galectin Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of GALT is $10.00 M
What is the all time high quarterly CFF for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly cash flow from financing activities is $47.40 M
What is Galectin Therapeutics quarterly CFF year-on-year change?
Over the past year, GALT quarterly cash flow from financing activities has changed by -$33.00 K (-0.33%)
What is Galectin Therapeutics TTM cash flow from financing activities?
The current TTM CFF of GALT is $40.38 M
What is the all time high TTM CFF for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM cash flow from financing activities is $50.74 M
What is Galectin Therapeutics TTM CFF year-on-year change?
Over the past year, GALT TTM cash flow from financing activities has changed by +$343.00 K (+0.86%)